Health Care & Life Sciences » Pharmaceuticals | Akebia Therapeutics Inc.

Akebia Therapeutics Inc.

Akebia Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.54
Market Cap
$516.24 M
Shares Outstanding
117.86 M
Public Float
103.41 M

Profile

Address
245 First Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.akebia.com
Updated 07/08/2019
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. It offers vadadustat, which is an oral therapy for the treatment of anemia due to chronic kidney disease.

Financials

View All

John P. Butler
President, Chief Executive Officer & Director
Cynthia Smith
Director